The Danish pharmaceutical company Novo Nordisk, with among other things the weight loss drug Wegovy and the diabetes drug Ozempic in its product portfolio, is lowering its full-year forecast.
After the announcement, the stock plummeted nearly 25 percent on the Copenhagen Stock Exchange, to the lowest level since February 2022.
According to the new forecast, Novo Nordisk now expects revenue growth of 8-14 percent instead of the previous forecast of 13-21 percent. The operating profit is expected to increase by 10-16 percent. The previous forecast was an operating profit of 16-24 percent.
At the same time, Novo Nordisk announces that Maziar Mike Doustdar has been appointed as the new CEO after Lars Fruergaard Jørgensen, who in May announced that he would leave the post.
